News

Ophthalmology Times23h
Survey data shows trends for AMD and DME treatments and future prospects
The survey shows the evolving landscape of nAMD and DME treatments, highlighting physician preferences, payer influences, and ...
The Bakersfield Californian5d
Biologic Competition, Payer Pressures, and Gene Therapy Momentum Define a Pivotal Moment in ...
Recently released research from Spherix Global Insights provides a timely look at the increasingly competitive and complex treatment landscape for neovascular age-related ...
Biologic Competition, Payer Pressures, And Gene Therapy Momentum Define A Pivotal Moment In Namd And DME Management, According To Spherix Global Insights
More than 70% of surveyed U.S. ophthalmologists anticipate a fundamentally transformed approach to managing nAMD and DME within the next five years.< ...
Retinal Biologics Market Set to Hit USD 49.5 Billion by 2032, Fueled by Aging Population and Precision Biologic Innovations - SNS Insider
SNS Insider Reveals Sharp Growth in U.S. Retinal Biologics Market, Valued at USD 9.70 Billion in 2023 Capturing Over 43% Global Share Amid FDA Approvals, VEGF-A Dominance, and Accelerating R&D in ...
pharmaphorum3d
After earlier rejection, high-dose Eylea clears FDA
Regeneron and Bayer's efforts to defend their lucrative eye disease therapy Eylea from competition have been boosted by FDA approval of a new high-dose formulation of the drug. The US regulator ...